Investors Careers FAQ Contact COMPANY TECHNOLOGIES PIPELINE NEWS & EVENTS CLINICAL TRIALS Careers at ViaCyte We are dedicated and relentless in the pursuit of functional cures for human diseases. ViaCyte employees are part of a professional team primarily focused on creating and commercializing cell replacement therapies for diabetes. We pride ourselves in our ability to retain and attract some of the most talented and passionate team members who create value everyday. ViaCyte provides a positive and collaborative work environment where ideas are welcomed and respected. This dynamic atmosphere has contributed to valuable research discoveries and encourages fun, enthusiastic, and active participation in the company’s success. Our most successful employees are driven by an entrepreneurial spirit with an understanding and appreciation for the risks and rewards of working in an emerging field within the biotechnology industry. We provide competitive salaries, benefits, and exciting opportunities for career development and growth. The team at ViaCyte is dedicated to innovation and driven to deliver a functional cure for type 1 diabetes and a next generation cure for all insulin-requiring diabetes. COMPANY TECHNOLOGIES PIPELINE NEWS & EVENTS CLINICAL TRIALS CONTACT Copyright 2021 ViaCyte, Inc. All Rights Reserved Terms of Service Privacy Policy We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT

Investors Careers FAQ Contact COMPANY TECHNOLOGIES PIPELINE NEWS & EVENTS CLINICAL TRIALS Stem Cell Engineering Creating immune-evasive cells for allogeneic cell replacement therapies Because type 1 diabetes is an autoimmune disease that develops when the body’s immune system attacks and destroys the insulin-producing cells in the pancreas, any implanted cell replacement therapies must evade the immune system. Also, like donor organs, any implantable human cell product will express its own unique immune ‘signature,’ and thus patients will not be a match for that signature. Approaches to address this allogeneic mismatch can be physical (PEC-Encap) or pharmacological (immunosuppressive therapy with PEC-Direct). Alternatively, we believe it may be possible to genetically engineer the stem cells such that the cells made from them, such as PEC-01 cells, evade the immune system (PEC-QT). COMPANY TECHNOLOGIES PIPELINE NEWS & EVENTS CLINICAL TRIALS CONTACT Copyright 2021 ViaCyte, Inc. All Rights Reserved Terms of Service Privacy Policy We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT